Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ankit K. Desai is active.

Publication


Featured researches published by Ankit K. Desai.


Molecular Genetics and Metabolism | 2017

The emerging phenotype of late-onset Pompe disease: A systematic literature review

Justin M. Chan; Ankit K. Desai; Zoheb B. Kazi; Kaitlyn Corey; Stephanie Austin; Lisa D. Hobson-Webb; Laura E. Case; Harrison N. Jones; Priya S. Kishnani

BACKGROUND Pompe disease is an autosomal recessive disorder caused by deficiency of the lysosomal glycogen-hydrolyzing enzyme acid α-glucosidase (GAA). The adult-onset form, late-onset Pompe disease (LOPD), has been characterized by glycogen accumulation primarily in skeletal, cardiac, and smooth muscles, causing weakness of the proximal limb girdle and respiratory muscles. However, increased scientific study of LOPD continues to enhance understanding of an evolving phenotype. PURPOSE To expand our understanding of the evolving phenotype of LOPD since the approval of enzyme replacement therapy (ERT) with alglucosidase alfa (Myozyme™/Lumizyme™) in 2006. METHODS All articles were included in the review that provided data on the charactertistics of LOPD identified via the PubMed database published since the approval of ERT in 2006. All signs and symptoms of the disease that were reported in the literature were identified and included in the review. RESULTS We provide a comprehensive review of the evolving phenotype of LOPD. Our findings support and extend the knowledge of the multisystemic nature of the disease. CONCLUSIONS With the advent of ERT and the concurrent increase in the scientific study of LOPD, the condition once primarily conceptualized as a limb-girdle muscle disease with prominent respiratory involvement is increasingly recognized to be a condition that results in signs and symptoms across body systems and structures.


JCI insight | 2017

Sustained immune tolerance induction in enzyme replacement therapy–treated CRIM-negative patients with infantile Pompe disease

Zoheb B. Kazi; Ankit K. Desai; Kathryn L. Berrier; R. Bradley Troxler; Raymond Y. Wang; Omar A. Abdul-Rahman; Pranoot Tanpaiboon; Nancy J. Mendelsohn; Eli Herskovitz; David Kronn; Michal Inbar-Feigenberg; Catherine Ward-Melver; Michelle Polan; Punita Gupta; Amy S. Rosenberg; Priya S. Kishnani

BACKGROUND Cross-reactive immunological material-negative (CRIM-negative) infantile Pompe disease (IPD) patients develop an immune response against enzyme replacement therapy (ERT) with alglucosidase alfa that nullifies ERT efficacy. Prophylactic immune tolerance induction (ITI) with rituximab, methotrexate, and IVIG successfully prevents development of deleterious rhGAA IgG antibodies; however, safety, likelihood of success, and long-term efficacy of ITI in a larger cohort remain unknown. METHODS Clinical data were analyzed for 19 CRIM-negative IPD patients who received ITI with rituximab, methotrexate, and IVIG in the ERT-naive setting (ERT+ITI) and compared to a historical cohort of 10 CRIM-negative IPD patients on ERT monotherapy. RESULTS ITI was safely tolerated, although infections were reported in 4 patients. Fourteen (74%) ERT+ITI patients were alive, with a median age of 44.2 months at their final assessment. The eldest survivor was 103.9 months old, with 100.2 months of follow-up after initiation of ERT+ITI. Death (n = 5) occurred at a median age of 29.2 months and was unrelated to the administration of ITI. Fifteen patients either did not seroconvert (n = 8) or maintained low titers (n = 7; defined as titers of ≤6,400 throughout the course of ERT) following ERT+ITI. Only one patient developed high and sustained antibody titers (defined as titers of ≥51,200 at or beyond 6 months on ERT). Left ventricular mass index (LVMI) decreased from a median of 248.5 g/m2 at baseline to 76.8 g/m2 at a median time from ERT+ITI initiation to 59 weeks. ERT+ITI significantly improved overall survival (P = 0.001), eliminated/reduced antibodies at values of ≤6,400 at week 52 on ERT (P = 0.0004), and improved LVMI at week 52 on ERT (P = 0.02) when compared with ERT monotherapy. CONCLUSION Evidence from this international cohort of CRIM-negative IPD patients further supports the safety, feasibility, and efficacy of ITI in the prevention of immune responses to ERT. TRIAL REGISTRATION Clinicaltrials.gov NCT01665326. FUNDING This research was supported in part by the Lysosomal Disease Network, a part of NIH Rare Diseases Clinical Research Network, and by a grant from Genzyme, a Sanofi company.


Molecular Genetics and Metabolism | 2017

Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation

Ankit K. Desai; Crista Walters; Heidi L. Cope; Zoheb B. Kazi; Stephanie DeArmey; Priya S. Kishnani

Patients with Pompe disease have realized significant medical benefits due to enzyme replacement therapy (ERT) infusions with alglucosidase alfa. However, regular infusions are time-consuming. Utilizing recommended infusion rates, infusion duration is 3h 45min for a patient receiving the standard dose of 20mg/kg, not including additional time needed for preparation of ERT, assessment of vital signs, intravenous access, and post-infusion monitoring. Recent studies have demonstrated increased effectiveness of higher dose of ERT (40mg/kg) in infantile-onset Pompe disease (IOPD), which increases the infusion duration to 6h 36min. Increased infusion durations compound the psychosocial burden on patients and families and potentially further disrupt family activities and obligations. We developed a stepwise infusion rate escalation protocol to administer higher dose ERT safely while decreasing infusion duration, which has been implemented in 15 patients to date. Reported here in detail are five patients with IOPD on 40mg/kg/weekly ERT in whom infusion duration was decreased with individualized, stepwise rate escalation. All patients tolerated rate escalations above the recommended rates without experiencing any infusion associated reactions and experienced a reduction in infusion duration by 1h and 24min with a corresponding increase in reported satisfaction. Our experience with ERT rate escalation is presented. SYNOPSIS A careful stepwise method of enzyme replacement therapy (ERT) rate escalation can safely reduce infusion duration in patients with Pompe disease.


Genetics in Medicine | 2018

An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease.

Zoheb B. Kazi; Ankit K. Desai; R. Bradley Troxler; David Kronn; Seymour Packman; Marta Sabbadini; William B. Rizzo; Katalin Scherer; Omar Abdul-Rahman; Pranoot Tanpaiboon; Sheela Nampoothiri; Neerja Gupta; Annette Feigenbaum; Dmitriy Niyazov; Langston Sherry; Reeval Segel; Alison McVie-Wylie; Crystal Sung; Alexandra M. Joseph; Susan Richards; Priya S. Kishnani

PurposeTo investigate immune tolerance induction with transient low-dose methotrexate (TLD-MTX) initiated with recombinant human acid α-glucosidase (rhGAA), in treatment-naïve cross-reactive immunologic material (CRIM)-positive infantile-onset Pompe disease (IOPD) patients.MethodsNewly diagnosed IOPD patients received subcutaneous or oral 0.4 mg/kg TLD-MTX for 3 cycles (3 doses/cycle) with the first 3 rhGAA infusions. Anti-rhGAA IgG titers, classified as high-sustained (HSAT; ≥51,200, ≥2 times after 6 months), sustained intermediate (SIT; ≥12,800 and <51,200 within 12 months), or low (LT; ≤6400 within 12 months), were compared with those of 37 CRIM-positive IOPD historic comparators receiving rhGAA alone.ResultsFourteen IOPD TLD-MTX recipients at the median age of 3.8 months (range, 0.7–13.5 months) had a median last titer of 150 (range, 0–51,200) at median rhGAA duration ~83 weeks (range, 36–122 weeks). One IOPD patient (7.1%) developed titers in the SIT range and one patient (7.1%) developed titers in the HSAT range. Twelve of the 14 patients (85.7%) that received TLD-MTX remained LT, versus 5/37 HSAT (peak 51,200–409,600), 7/37 SIT (12,800–51,000), and 23/37 LT (200–12,800) among comparators.ConclusionResults of TLD-MTX coinitiated with rhGAA are encouraging and merit a larger longitudinal study.


Molecular Genetics and Metabolism | 2017

Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T > G “late-onset” GAA variant

Mugdha Rairikar; Laura E. Case; Lauren Bailey; Zoheb B. Kazi; Ankit K. Desai; Kathryn L. Berrier; Julie Coats; Rachel Gandy; Rebecca Quinones; Priya S. Kishnani


Molecular Genetics and Metabolism | 2016

Prophylactic immune modulation in infantile Ρompe disease using low-dose methotrexate induction: A safe, inexpensive, widely accessible, and efficacious strategy

Zoheb B. Kazi; Ankit K. Desai; Angelika Erwin; Chris Makris; Bradley Troxler; David Kronn; Seymour Packman; Marta Sabbadini; Jean-Marc Nuoffer; James D. Weisfeld-Adams; William B. Rizzo; Clarisa Maxit; Marianne Rohrbach; Diana Ballhausen; Katalyn Scherer; Omar A. Abdul-Rahman; Alexandra M. Joseph; Alison McVie-Wylie; Susan Richards; Priya S. Kishnani


Molecular Genetics and Metabolism | 2018

An immune tolerance approach using methotrexate in the naïve setting of patients treated with a therapeutic protein: Experience in infantile Pompe disease

Ankit K. Desai; Zoheb B. Kazi; Angelika Erwin; Bradley Troxler; David Kronn; Seymour Packman; Marta Sabbadini; Jean-Marc Nuoffer; James Weisfield-Adams; William B. Rizzo; Clarisa Maxit; Marianne Rohrbach; Diana Ballhausen; Katalin Scherer; Omar A. Abdul-Rahman; Pranoot Tanpaiboon; Sheela Nampoothiri; Neerja Gupta; Annette Feigenbaum; Dmitriy Niyazov; Sherry Langston; Alison McVie-Wylie; Crystal Sung; Alexandra M. Joseph; Susan Richards; Priya S. Kishnani


Molecular Genetics and Metabolism | 2018

A prediction model to identify infantile Pompe disease (IPD) patients at high-risk of developing significant anti-drug antibodies (ADA) utilizing acid α-glucosidase (GAA ) variants and HLA-type

Zoheb B. Kazi; Ankit K. Desai; Rebecca Martin; Frances Terry; William Martin; Anne S. De Groot; Priya S. Kishnani


Molecular Genetics and Metabolism | 2017

High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient

Mugdha Rairikar; Zoheb B. Kazi; Ankit K. Desai; Crista Walters; Amy S. Rosenberg; Priya S. Kishnani


Molecular Genetics and Metabolism | 2017

A newborn screening dilemma: when to treat Pompe disease with c.-32-13TgG IVS splice site mutation

Lauren Bailey; Mugdha Rairikar; Ankit K. Desai; Zoheb B. Kazi; Laura E. Case; Priya S. Kishnani

Collaboration


Dive into the Ankit K. Desai's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David Kronn

New York Medical College

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Omar A. Abdul-Rahman

University of Mississippi Medical Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge